Press Release | Fri Mar 14, 2014 6:05am EDT

Achillion Announces Oral Presentations Given at APASL 2014 Detailing Clinical Activity of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV

* Reuters is not responsible for the content in this press release.